LDOS · Q1 2026 Earnings
BullishLeidos
Reported May 5, 2026
30-second summary
Q1 revenue grew 4% YoY to $4.40B with non-GAAP EPS of $3.13 and adjusted EBITDA margin of 14.0% — a clean restart after the shutdown-compressed Q4, with book-to-bill of 0.8 in-quarter but TTM at 1.1 and backlog holding at $48.4B. Management raised FY26 revenue by $0.50B at midpoint to $18.00–18.40B (reflecting the Entrust close), lifted EPS modestly by $0.05 to $12.10–12.50, and raised operating cash flow to ~$1.80B, while reaffirming EBITDA margin at "mid 13%" and explicitly flagging Q2 as the "likely low point" in revenue growth and margin for the year. The tone has shifted from Q4's strategy-execution framing to Q1's offensive posture — Bell saying Leidos is "out of the blocks in 2026 playing offense" with $9B of defense tech awards in 15 months and a stated path to "thousands" of unit production runs this decade.
Headline numbers
EPS
Q1 FY2026
$3.13
Revenue
Q1 FY2026
$4.40B
+4.0% YoY
Gross margin
Q1 FY2026
17.3%
Free cash flow
Q1 FY2026
$0.27B
Operating margin
Q1 FY2026
11.5%
Key financials
Q1 FY2026| Metric | Q1 FY2026 | YoY | Q4 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $4.40B | +4.0% | $4.21B | +4.6% |
| EPS | $3.13 | — | $2.76 | +13.4% |
| Gross margin | 17.3% | — | 17.6% | -30bps |
| Operating margin | 11.5% | — | 11.2% | +30bps |
| Free cash flow | $0.27B | — | $0.45B | -40.3% |
Guidance
Leidos raised full-year FY2026 revenue, EPS, and operating cash flow guidance while reaffirming EBITDA margin; Q1 results met expectations with 4% YoY revenue growth and strong backlog momentum.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Revenue | Q1 FY2026 | Guidance implied within $17.5B - $17.9B annual range | $4.40 billion | In-line with expectations | Met |
| Non-GAAP Diluted EPS | Q1 FY2026 | Guidance implied within $12.05 - $12.45 annual range | $3.13 | In-line with expectations | Met |
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| Revenue | FY 2026 | $17.50 - $17.90 billion | $18.00 - $18.40 billion | +$0.50B at both ends (+2.8% low, +2.8% high) | Raised |
| Non-GAAP Diluted EPS | FY 2026 | $12.05 - $12.45 | $12.10 - $12.50 | +$0.05 at both ends (+0.4% low, +0.4% high) | Raised |
| Cash Flows Provided by Operating Activities | FY 2026 | Approximately $1.75 billion | Approximately $1.80 billion | +$0.05 billion (+2.9%) | Raised |
Reaffirmed unchanged this quarter: Adjusted EBITDA Margin (Mid 13%)
Segment KPIs
Q1 FY2026| Segment | Q1 FY2026 | YoY |
|---|---|---|
| Intelligence & Digital | $1.513B | +7.0% |
| Health | $1.188B | — |
| Homeland | $0.816B | +6.0% |
| Defense | $0.883B | +0.5% |
Other KPIs
Q1 FY2026| Segment | Q1 FY2026 |
|---|---|
| Adjusted EBITDA | $614 million |
| Adjusted EBITDA Margin | 14.0% |
| Total Backlog | $48.4 billion |
| Funded Backlog | $9.6 billion |
| Book-to-Bill Ratio | 0.8 |
| Trailing Twelve Month Book-to-Bill | 1.1 |
| Operating Cash Flow | $301 million |
| Net Bookings | $3.3 billion |
Management tone
Narrative arc: DOGE freeze (Q1-25) → logjam breaking up (Q2-25) → awards in the numbers (Q3-25) → execution mode with tripled capex (Q4-25) → playing offense with production-at-scale visibility (Q1-26).
AI framing has migrated from positioning to operating model in three quarters. Three quarters ago AI was a forward opportunity referenced in pipeline math; on Q3 it was the re-won counterterrorism contract proof point; this quarter Bell's anchor is "We are not reacting to AI. AI is nothing new to Leidos. We are scaling with AI... AI is an accelerant of our business model." That is a categorically different posture — AI as competitive moat embedded in execution, not as a strategic risk being navigated. The shift signals management believes the cost-deflation pressure on services contractors is being out-run by Leidos's mission-trust positioning rather than mitigated.
Defense framing has shifted from "managing the legacy mix" to "thousands-of-units production at scale" — but the segment revenue print contradicts the rhetoric. A year ago Defense was a HSD-LDD growth segment with margin caveats; on Q4 it printed +1% with airborne-margin ebb flagged; this quarter Bell quantifies "we've earned over $9 billion of awards for our defense tech business in the last 15 months alone... a path to another $8 billion in our next 12-month pipeline... production runs of thousands of these products in this decade alone." The forward visibility is the most concrete management has offered, but Q1 Defense revenue grew 0.5% and margins are pressured by fixed-price development delays. The bookings-to-revenue lag is the bridge management is asking investors to underwrite — and it's now a multi-quarter ask, not a single-quarter timing issue.
Entrust has compressed from a Q2-close pending deal to immediately accretive in one quarter. On Q4 Bell framed Entrust as Q2-close with phased accretion and FY26 guidance explicitly excluding it. This quarter: "Integration is ahead of schedule, the cultural alignment is seamless, and the financial upside is already surfacing in our consolidated numbers... we've raised 2026 guidance reflecting the deal... now expect the deal to be accretive to non-GAAP EPS and cash in 2026." Energy pipeline reframed to $10B (230% post-close growth) with first energy generation plant RFP received. The execution velocity here is the most credible operational claim in the print — but the $0.05 EPS raise versus a $0.50B revenue raise tells you the accretion management is claiming is modest in dollar terms, with most of the upside being deferred to 2027+.
Q2 as "likely low point" is a tone hedge management has not previously made explicit. Across Q2-25, Q3-25, and Q4-25 management hedged on shutdown timing and award definitization but never named a specific quarter as the trough. Bell's "we view Q1 revenue overperformance as a pull forward from the second quarter, as opposed to a notable market reacceleration" paired with "Q2 as the likely low point" tells you Q1's +4% is the better-than-expected print being pre-deflated for the next quarter. The cyber pipeline at $24B (+21% post-Kudu) and the long-term bullish framing are real, but Q2 being flagged as the low point on both revenue growth and margin is the one explicit near-term hedge investors need to model.
The "playing offense" frame is the most aggressive posture management has taken in this cycle. "Leidos is out of the blocks in 2026 playing offense" and "extremely bullish on long-term outlook" are notably more declarative than Q4's "strategy execution mode" or Q3's "thriving through adversity." Combined with the specific production-run language, the $24B cyber pipeline, the $10B energy pipeline, and the $8B defense tech 12-month pipeline, management is positioning the long-term story as the headline — and asking investors to look past Q2.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Noah Poponek · Goldman Sachs
Multi-year outlook for health segment given VBA exam dynamics, revenue flatness, and margin compression. Is this a one-year reset or multi-year revenue decline with margin reset?
Management expects health to be a platform with modest reset this year but bullish long-term growth trajectory. Margins expected to stay above 20% threshold. New revenue streams (Military One Source, My Service Treatment Record pilot, behavioral health, rural health) positioned as growth drivers. Fixed-price contracts incentivize operational efficiency.
John Gillespie · Citi
Clarification on shape of year regarding revenue and margins, specifically potential Q2 softness and how the year builds from there.
Q1 benefited from some pull-forward from Q2. Q2 expected to be similar to Q1 or slightly down due to program transitions and wind-downs. Significant step-function growth anticipated in Q3-Q4 with high margin rates. Momentum expected to carry into 2027.
Josh Korn · Wells Fargo
Clarification on $350 million CapEx guidance given only $31 million spent in Q1. Is this still the plan and how does spending profile look throughout the year?
Elevated CapEx need hasn't risen in Q1 as anticipated. Higher spend expected in Q2 tied to program requirements. Management takes disciplined approach, only spending when program triggers are activated. Whether full $350M is spent depends on program layering, but commitment to being good stewards of capital remains.
Seth Seisman · JP Morgan
Given market skepticism on services growth despite product momentum, how does intelligence and digital business perform if overall defense budget grows at even 50% of administration's request?
Intelligence Community budgets have grown 4-5% annually since 2022 with expectation to continue. Classified budgets showing significant money for digital infrastructure. AI positioned as propellant not disruptor. Digital infrastructure business is foundation for AI adoption. Company leveraging digital infrastructure and cybersecurity with AI to move up value chain.
Toby Somer · Truro Securities
Outlook for health business including existing portfolio, VBA exams, expansion areas targeted, and how composition and margins may change.
Volumes remain high in Q1 despite fourth vendor provisioning. VBA expected to maintain elevated volumes through backlog reduction. Company investing in technology and innovative business models. Growth pillars identified: managed health, behavioral health, rural health. Military One Source award and My Service Treatment Record pilot indicate digital ecosystem strategy.
Answers to last quarter's watch list
What to watch into next quarter
Q2 revenue growth and margin print against management's "likely low point" framing. Bell explicitly named Q2 as the trough on both metrics. Watch whether Q2 revenue grows at all YoY (Q2-25 base $4.25B) and whether EBITDA margin holds at or above 13.0%. A Q2 revenue YoY decline or a sub-13% margin print would suggest the H2 acceleration thesis is starting from a lower-than-guided base.
Defense segment growth trajectory — third consecutive sub-mid-single-digit print would damage the segment-mix story. Q4 +1%, Q1 +0.5%. If Q2 prints below mid-single-digits again, the "thousands of units" production-at-scale framing becomes a 2027+ story rather than a 2026 contributor, and the segment-mix-driven margin thesis weakens materially.
Q2 book-to-bill recovery above 1.0. Q1 at 0.8 with backlog stepping down $0.6B is the single soft data point in the print. Management points to $6B of Q2-Q3 submits; watch whether Q2 lands above 1.0 and whether named defense tech awards (the $8B 12-month pipeline) show up by name. A second sub-1.0 quarter would force the H2 acceleration thesis to lean entirely on Q3 conversion.
CapEx pacing toward $350M. Q1 at $31M means $319M needed across the remaining three quarters. Watch whether Q2 steps up to $80-100M as Korn's Q&A implied or whether undershoot is becoming likely. CapEx undershoot would lift FCF meaningfully above the raised $1.80B OCF guide.
Health segment progression from flat to positive YoY. Q4 -9% → Q1 0% is the inflection; positive YoY growth is the next bar. Watch whether the Military One Source award and My Service Treatment Record pilot show up in segment revenue and whether the 20% margin floor commitment holds through the fourth-vendor capacity ramp.
Entrust accretion visibility — does H2 deliver the synergies "already surfacing" in Q1? The $0.05 EPS raise is modest against management's confident integration language. If H2 prints show Entrust contributing materially above the conservative implied uplift, the FY guide proves sandbagged; if H2 prints show Entrust at corporate-average profitability, the conservative guide proves realistic.
Sources
- Leidos Q1 2026 Press Release — https://www.sec.gov/Archives/edgar/data/1336920/000133692026000167/ldos040326q1pressreleaseex.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.